Rosuvastatin and thapsigargin modulate γ-secretase gene expression and APP processing in a human neuroglioma model

Alessio Crestini, Paola Piscopo, Mariavittoria Iazeolla, Diego Albani, Roberto Rivabene, Gianluigi Forloni, Annamaria Confaloni

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder leading to slow neuronal loss in several brain regions. It is characterised by the presence of cerebral senile plaques comprised of aggregated amyloid-β peptides. Transcriptional regulation of the γ-secretase complex, which cleaves the β-amyloid precursor protein to produce Aβ-peptides, could modulate the pathological phenotype of AD patients. This study investigates whether rosuvastatin, an HMG-CoA reductase inhibitor, modulates the expression of genes involved in the function of the γ-secretase complex, in a human cellular model for Aβ peptide accumulation. In particular, we analysed the effect of the statin combined with apoptotic induction. Experimental apoptosis was induced by thapsigargin treatment, a drug that depletes intracellular calcium stores via inhibition of the calcium ATPase pump. Notably, systemic calcium dysregulation accompanies almost all of the brain pathology processes observed in AD. We found differential transcriptional regulation of some γ-secretase cofactors relative to rosuvastatin treatment, in cells expressing Swedish mutant APP. Interestingly, this statin downregulated the transcription of some enzyme cofactors, similar to treatment with thapsigargin. However, rosuvastatin neither affected the basal Aβ levels nor counteracted APP processing or Aβ over-production triggered by the thapsigargin. Our results provide evidence that rosuvastatin alters gene expression of the γ-secretase complex without affecting enzyme activity.

Original languageEnglish
Pages (from-to)461-469
Number of pages9
JournalJournal of Molecular Neuroscience
Volume43
Issue number3
DOIs
Publication statusPublished - Mar 2011

Fingerprint

Amyloid Precursor Protein Secretases
Thapsigargin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Gene Expression
Alzheimer Disease
Peptides
Calcium
Calcium-Transporting ATPases
Amyloid beta-Protein Precursor
Coenzymes
Amyloid Plaques
Brain
Amyloid
Neurodegenerative Diseases
Therapeutics
Down-Regulation
Apoptosis
Pathology
Phenotype
Rosuvastatin Calcium

Keywords

  • Aβ peptides
  • Gene expression
  • H4 neuroglioma cells
  • Statin
  • Thapsigargin

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Cite this

Rosuvastatin and thapsigargin modulate γ-secretase gene expression and APP processing in a human neuroglioma model. / Crestini, Alessio; Piscopo, Paola; Iazeolla, Mariavittoria; Albani, Diego; Rivabene, Roberto; Forloni, Gianluigi; Confaloni, Annamaria.

In: Journal of Molecular Neuroscience, Vol. 43, No. 3, 03.2011, p. 461-469.

Research output: Contribution to journalArticle

Crestini, Alessio ; Piscopo, Paola ; Iazeolla, Mariavittoria ; Albani, Diego ; Rivabene, Roberto ; Forloni, Gianluigi ; Confaloni, Annamaria. / Rosuvastatin and thapsigargin modulate γ-secretase gene expression and APP processing in a human neuroglioma model. In: Journal of Molecular Neuroscience. 2011 ; Vol. 43, No. 3. pp. 461-469.
@article{9a1e2253ee164de0b1f085e3b97c55f6,
title = "Rosuvastatin and thapsigargin modulate γ-secretase gene expression and APP processing in a human neuroglioma model",
abstract = "Alzheimer's disease (AD) is a progressive neurodegenerative disorder leading to slow neuronal loss in several brain regions. It is characterised by the presence of cerebral senile plaques comprised of aggregated amyloid-β peptides. Transcriptional regulation of the γ-secretase complex, which cleaves the β-amyloid precursor protein to produce Aβ-peptides, could modulate the pathological phenotype of AD patients. This study investigates whether rosuvastatin, an HMG-CoA reductase inhibitor, modulates the expression of genes involved in the function of the γ-secretase complex, in a human cellular model for Aβ peptide accumulation. In particular, we analysed the effect of the statin combined with apoptotic induction. Experimental apoptosis was induced by thapsigargin treatment, a drug that depletes intracellular calcium stores via inhibition of the calcium ATPase pump. Notably, systemic calcium dysregulation accompanies almost all of the brain pathology processes observed in AD. We found differential transcriptional regulation of some γ-secretase cofactors relative to rosuvastatin treatment, in cells expressing Swedish mutant APP. Interestingly, this statin downregulated the transcription of some enzyme cofactors, similar to treatment with thapsigargin. However, rosuvastatin neither affected the basal Aβ levels nor counteracted APP processing or Aβ over-production triggered by the thapsigargin. Our results provide evidence that rosuvastatin alters gene expression of the γ-secretase complex without affecting enzyme activity.",
keywords = "Aβ peptides, Gene expression, H4 neuroglioma cells, Statin, Thapsigargin",
author = "Alessio Crestini and Paola Piscopo and Mariavittoria Iazeolla and Diego Albani and Roberto Rivabene and Gianluigi Forloni and Annamaria Confaloni",
year = "2011",
month = "3",
doi = "10.1007/s12031-010-9465-3",
language = "English",
volume = "43",
pages = "461--469",
journal = "Journal of Molecular Neuroscience",
issn = "0895-8696",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - Rosuvastatin and thapsigargin modulate γ-secretase gene expression and APP processing in a human neuroglioma model

AU - Crestini, Alessio

AU - Piscopo, Paola

AU - Iazeolla, Mariavittoria

AU - Albani, Diego

AU - Rivabene, Roberto

AU - Forloni, Gianluigi

AU - Confaloni, Annamaria

PY - 2011/3

Y1 - 2011/3

N2 - Alzheimer's disease (AD) is a progressive neurodegenerative disorder leading to slow neuronal loss in several brain regions. It is characterised by the presence of cerebral senile plaques comprised of aggregated amyloid-β peptides. Transcriptional regulation of the γ-secretase complex, which cleaves the β-amyloid precursor protein to produce Aβ-peptides, could modulate the pathological phenotype of AD patients. This study investigates whether rosuvastatin, an HMG-CoA reductase inhibitor, modulates the expression of genes involved in the function of the γ-secretase complex, in a human cellular model for Aβ peptide accumulation. In particular, we analysed the effect of the statin combined with apoptotic induction. Experimental apoptosis was induced by thapsigargin treatment, a drug that depletes intracellular calcium stores via inhibition of the calcium ATPase pump. Notably, systemic calcium dysregulation accompanies almost all of the brain pathology processes observed in AD. We found differential transcriptional regulation of some γ-secretase cofactors relative to rosuvastatin treatment, in cells expressing Swedish mutant APP. Interestingly, this statin downregulated the transcription of some enzyme cofactors, similar to treatment with thapsigargin. However, rosuvastatin neither affected the basal Aβ levels nor counteracted APP processing or Aβ over-production triggered by the thapsigargin. Our results provide evidence that rosuvastatin alters gene expression of the γ-secretase complex without affecting enzyme activity.

AB - Alzheimer's disease (AD) is a progressive neurodegenerative disorder leading to slow neuronal loss in several brain regions. It is characterised by the presence of cerebral senile plaques comprised of aggregated amyloid-β peptides. Transcriptional regulation of the γ-secretase complex, which cleaves the β-amyloid precursor protein to produce Aβ-peptides, could modulate the pathological phenotype of AD patients. This study investigates whether rosuvastatin, an HMG-CoA reductase inhibitor, modulates the expression of genes involved in the function of the γ-secretase complex, in a human cellular model for Aβ peptide accumulation. In particular, we analysed the effect of the statin combined with apoptotic induction. Experimental apoptosis was induced by thapsigargin treatment, a drug that depletes intracellular calcium stores via inhibition of the calcium ATPase pump. Notably, systemic calcium dysregulation accompanies almost all of the brain pathology processes observed in AD. We found differential transcriptional regulation of some γ-secretase cofactors relative to rosuvastatin treatment, in cells expressing Swedish mutant APP. Interestingly, this statin downregulated the transcription of some enzyme cofactors, similar to treatment with thapsigargin. However, rosuvastatin neither affected the basal Aβ levels nor counteracted APP processing or Aβ over-production triggered by the thapsigargin. Our results provide evidence that rosuvastatin alters gene expression of the γ-secretase complex without affecting enzyme activity.

KW - Aβ peptides

KW - Gene expression

KW - H4 neuroglioma cells

KW - Statin

KW - Thapsigargin

UR - http://www.scopus.com/inward/record.url?scp=79955850821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955850821&partnerID=8YFLogxK

U2 - 10.1007/s12031-010-9465-3

DO - 10.1007/s12031-010-9465-3

M3 - Article

C2 - 20981578

AN - SCOPUS:79955850821

VL - 43

SP - 461

EP - 469

JO - Journal of Molecular Neuroscience

JF - Journal of Molecular Neuroscience

SN - 0895-8696

IS - 3

ER -